Pedram Razavi, MD, PhD

Pedram Razavi, MD, PhD, of Memorial Sloan Kettering Cancer Center

Articles by Pedram Razavi, MD, PhD

Pedram Razavi, MD, PhD, breast medical oncologist, director, Liquid Biopsy & Genomics, Memorial Sloan Kettering Cancer Center; Dara S. Ross, MD, associate attending pathologist, Memorial Sloan Kettering Cancer Center

Evolving ESR1 Mutation Testing Directions Complicate the Future of Metastatic Breast Cancer Management: With Pedram Razavi, MD, PhD; and Dara S. Ross, MD

ByPedram Razavi, MD, PhD,Dara S. Ross, MD

May 20th 2026

Drs Razavi and Ross note the evolution of ESR1 mutation–directed breast cancer management, including the role of genomic testing at metastatic recurrence.

Pedram Razavi, MD, PhD

Articles by Pedram Razavi, MD, PhD

Evolving ESR1 Mutation Testing Directions Complicate the Future of Metastatic Breast Cancer Management: With Pedram Razavi, MD, PhD; and Dara S. Ross, MD

Latest Updated Articles

Trending on OncLive

Cracking the KRAS Code: How Daraxonrasib Is Reshaping Pancreatic Cancer and Beyond

ctDNA MRD Status Predicts OS Benefit With Adjuvant Chemotherapy in Resected CRC Liver Metastases

FDA Accepts NDA for Varegacestat in Desmoid Tumors

INCB123667 Advances to Phase 3 Following Encouraging Activity in Platinum-Resistant Ovarian Cancer

Neoadjuvant/Adjuvant Pembrolizumab Yields EFS Benefits Regardless of Surgical Outcomes in HNSCC